Abstract
No public abstract is available from the verified source records.
Michael Z. Wang, Kathryn Secrist, Ozan S. Kumru, Sangeeta B. Joshi, David B. Volkin
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
europepmc
Confidence 96%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Measles.
10.1016/s0140-6736(21)02004-3 · 2022
On the Path to Measles and Rubella Elimination Following Rubella-Containing Vaccine Introduction, 2000–2023, Namibia.
10.3390/vaccines12090957 · 2024
The basic reproduction number (R0) of measles: a systematic review.
10.1016/s1473-3099(17)30307-9 · 2017
Measles Vaccine.
10.1089/vim.2017.0143 · 2017
Rubella.
10.1016/s0140-6736(21)02691-x · 2022
Molecular and Structural Insights into the Life Cycle of Rubella Virus.
10.1128/jvi.02349–02320 · 2021
Measles immunity and immunosuppression.
10.1016/j.coviro.2020.08.002 · 2021
CD150 is a member of a family of genes that encode glycoproteins on the surface of hematopoietic cells.
10.1007/s002510100337 · 2001
Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens.
10.1126/science.aay6485 · 2019
Efficiency of Measles Virus Entry and Dissemination through Different Receptors.
10.1128/jvi.76.15.7460-7467.2002 · 2002
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.
10.1080/21645515.2015.1122146 · 2016
Rubella.
Kept as external metadata until matched
Rubella (German Measles) and Congenital Deformities.
10.1056/nejm194902172400706 · 1949
Estimates of the basic reproduction number for rubella using seroprevalence data and indicator-based approaches.
10.1371/journal.pcbi.1008858 · 2022
Studies of immunization with living rubella virus. Trials in children with a strain cultured from an aborted fetus.
10.1001/archpedi.1965.02090030401007 · 1965
The History of Rubella and Rubella Vaccination Leading to Elimination.
10.1086/505950 · 2006
Identification of the Myelin Oligodendrocyte Glycoprotein as a Cellular Receptor for Rubella Virus.
10.1128/jvi.05398-11 · 2011
Measles.
10.1016/s0140-6736(10)62352-5 · 2012
SIB Swiss Institute of Bioinformatics. Matonaviridae.
Kept as external metadata until matched
Progress Toward Measles Elimination — Worldwide, 2000–2023.
10.15585/mmwr.mm7345a4 · 2024
Measles once again.
10.1016/s1473-3099(11)70152-9 · 2011
Progress Toward Rubella and Congenital Rubella Syndrome Elimination — Worldwide, 2012–2022.
10.15585/mmwr.mm7308a2 · 2024
Measles and Measles-Rubella Combination Vaccines: Supply and Demand Update.
Kept as external metadata until matched
Measles 2025.
10.1056/nejmra250451610.1056/nejmra2504516 · 2025
Modeling Reemergence of Vaccine-Eliminated Infectious Diseases Under Declining Vaccination in the US.
10.1001/jama.2025.6495 · 2025
WHO-CDC measles report & the State of measles vaccination in lower-income countries.
2024
Measles Cases Rise Globally, While the Americas Region Regains Measles Elimination Status.
Kept as external metadata until matched
PAHO Calls for Regional Action as the Americas Lose Measles Elimination Status.
Kept as external metadata until matched
14th Meeting of the European Regional Verification Commission for Measles and Rubella Elimination (RVC).
Kept as external metadata until matched
Progress towards measles elimination - worldwide, 2000–2024.
10.15585/mmwr.mm7345a4 · 2025
Progress Toward Rubella and Congenital Rubella Syndrome Elimination - Worldwide, 2012-2024.
10.15585/mmwr.mm7528a1 · 2026
The path to eradication of rubella.
10.1016/j.vaccine.2023.11.014 · 2023
Progress Toward Rubella Elimination — World Health Organization European Region, 2005–2019.
10.15585/mmwr.mm7023a1 · 2021
Twelfth meeting of the European Regional Verification Commission for Measles and Rubella Elimination.
Kept as external metadata until matched
Genetic characterization of measles vaccine strains.
10.1093/infdis/jir097 · 2011
Rubella vaccines: past, present and future.
10.1017/s0950268800048640 · 1991
Enders and measles virus vaccine--a reminiscence.
10.1007/978-3-540-70523-9_1 · 2009
Measles 50 Years After Use of Measle Vaccine.
10.1016/j.idc.2015.08.001 · 2015
MMR and MMRV vaccines.
10.1016/j.vaccine.2017.07.051 · 2018
Making Vaccination Policy: The Experience with Rubella.
10.1086/515062 · 1999
Rubella Eradication: Not Yet Accomplished, but Entirely Feasible.
10.1093/infdis/jiaa530 · doi-reference
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.
10.1016/j.heliyon.2024.e34927 · doi-reference
Large-scale and cost-effective production of recombinant human serum albumin (rHSA) in transgenic Bombyx mori cocoons.
10.1016/j.ijbiomac.2023.125527 · doi-reference
Programming cytomegalovirus as an HIV vaccine.
10.1016/j.it.2023.02.001 · doi-reference
Attenuated measles virus as a vaccine vector.
10.1016/j.vaccine.2007.01.064 · doi-reference
Sabin inactivated polio vaccine upstream process development using fixed-bed bioreactor technology.
10.1016/j.vaccine.2025.126950 · doi-reference
Effective Approaches to Combat Vaccine Hesitancy.
10.1097/inf.0000000000003499 · doi-reference
Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective.
10.1080/21645515.2022.2050123 · doi-reference
Identification of potential vaccines for use with microarray patches in low- and middle-income countries: An assessment from the Vaccine Innovation Prioritisation Strategy Alliance.
10.1016/j.vaccine.2025.126996 · doi-reference
Innovations in vaccine delivery: increasing access, coverage, and equity and lessons learnt from measles and rubella elimination.
10.1007/s13346-022-01130-9 · doi-reference
Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naive infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].
10.1186/s13063-022-06493-5 · doi-reference
A microneedle patch containing measles vaccine is immunogenic in non-human primates.
10.1016/j.vaccine.2015.02.074 · doi-reference
Measles vaccination using a microneedle patch.
10.1016/j.vaccine.2012.09.062 · doi-reference
Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial.
10.3390/vaccines11111725 · doi-reference
A Microneedle Patch for Measles and Rubella Vaccination Is Immunogenic and Protective in Infant Rhesus Macaques.
10.1093/infdis/jiy139 · doi-reference
Thermostability of Measles and Rubella Vaccines in a Microneedle Patch.
10.1002/adtp.202100095 · doi-reference
Microneedle-Based Vaccine Delivery: Review of an Emerging Technology.
10.1208/s12249-022-02250-8 · doi-reference
A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
10.1016/s0140-6736(24)00532-4 · doi-reference
Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects.
10.1016/j.biomaterials.2017.02.040 · doi-reference
Developing a stabilizing formulation of a live chimeric dengue virus vaccine dry coated on a high-density microarray patch.
10.3390/vaccines9111301 · doi-reference
Development of a thermostable microneedle patch for influenza vaccination.
10.1002/jps.24283 · doi-reference
Development of stabilizing formulations of a trivalent inactivated poliovirus vaccine in a dried state for delivery in the Nanopatch™ microprojection array.
10.1016/j.xphs.2018.01.027 · doi-reference
A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination.
10.1016/j.coviro.2020.05.005 · doi-reference
Microarray patches: scratching the surface of vaccine delivery.
10.1080/14760584.2023.2270598 · doi-reference
Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges.
10.3389/fpubh.2022.809675 · doi-reference
Targeting skin dendritic cells to improve intradermal vaccination.
10.1007/82_2010_118 · doi-reference
Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques.
10.1073/pnas.1017334108 · doi-reference
Heat-stable measles vaccine produced by spray drying.
10.1016/j.vaccine.2009.11.024 · doi-reference
Dry powder measles vaccine: particle deposition, virus replication, and immune response in cotton rats following inhalation.
10.1016/j.vaccine.2010.10.020 · doi-reference
Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine.
10.1089/jamp.2007.0658 · doi-reference
It's time to change how we vaccinate for measles.
10.1016/j.vaccine.2025.127382 · doi-reference
Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial.
10.1016/s0140-6736(99)95140-1 · doi-reference
Safety and immunogenicity of dry powder measles vaccine administered by inhalation: a randomized controlled Phase I clinical trial.
10.1016/j.vaccine.2014.09.071 · doi-reference
A randomized, controlled trial of an aerosolized vaccine against measles.
10.1056/nejmoa1407417 · doi-reference
Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective.
10.1038/s41467-024-49443-2 · doi-reference
A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
10.1073/pnas.2220403120 · doi-reference
Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis.
10.1016/j.vaccine.2007.11.010 · doi-reference
Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine.
10.1128/cvi.00354-10 · doi-reference
Alternative routes of measles immunization: a review.
10.1006/biol.1997.0103 · doi-reference
Current progress in pulmonary delivery of measles vaccine.
10.1586/14760584.2014.915753 · doi-reference